#None #Plano #FDA Clearance #Vesalio #NeVa VS

Vesalio's Expansion in Neurovascular Intervention

Vesalio, a leader in vascular intervention, has solidified its position in the global market by announcing the CE Mark certification and European launch of two new neurovascular products—the NeVa™ VS, designed to tackle cerebral vasospasm, and the NeVa™ 3.0 mm Thrombectomy System, aimed at enhancing stroke treatment options. In tandem, the company has acquired additional FDA 510(k) clearance which expands the use of its aspiration catheters in the U.S.

Diane Demet Tangun, Vice President of Market Development at Vesalio, emphasized that these approvals mark a significant advancement for the company, showcasing the strategic development of its neurovascular portfolio. This growth is pivotal as Vesalio focuses on delivering specialized solutions for intricate vascular challenges and improving physician support with innovative technologies.

Addressing Unmet Needs in Cerebral Vasospasm

The NeVa VS device has been introduced to address a crucial gap in managing cerebral vasospasm that follows aneurysmal subarachnoid hemorrhage (aSAH). This condition can lead to serious complications, including delayed cerebral ischemia and neurological deterioration. Unlike traditional treatments like balloon angioplasty, NeVa VS enhances safety while allowing for the preservation of distal blood flow during interventions on critically narrowed vessels. Clinical evidence from the VITAL study reveals that an overwhelming 93.2% of vessels treated with NeVa VS required no further intervention, highlighting its potential as a definitive therapeutic option.

Dr. Ameer Hassan, an interventional radiologist, shares his positive experience, asserting that NeVa VS is not only controlled but also protective of vascular flow in critical situations—a significant advantage over standard angioplasty methods.

Advancements in Stroke Treatment with NeVa 3.0 mm

In addition to the NeVa VS, Vesalio's newly CE marked NeVa 3.0 mm Thrombectomy device introduces their proprietary Drop Zone™ technology to favorably handle smaller and more complex arterial structures. This advancement is expected to broaden the pool of patients eligible for mechanical thrombectomy, thereby enhancing treatment success rates. Dr. Roland Schwab, an interventional neuroradiologist, expressed enthusiasm about this addition, eager to see its implications in challenging cases where previous NeVa solutions were unsuitable.

Moreover, Vesalio's newly acquired FDA 510(k) clearance expands the functionality of their neurovascular and peripheral aspiration catheters to include distal access through microcatheter delivery. This update significantly enhances the versatility and applications of their catheter portfolio in various medical interventions.

The Vision Ahead

Steve Rybka, the CEO of Vesalio, underscores the company's dedication to broadening access to its cutting-edge technologies across the globe. The recent certifications and clearances exemplify Vesalio's comprehensive approach to develop a well-rounded and adaptable product lineup. As they gear up for the next phase of commercial growth, these milestones provide a robust platform for the company's future initiatives.

Founded in 2017, Vesalio specializes in medical devices that cater to thromboembolic vascular diseases. Their renowned NeVa™, enVast™, and pVasc™ platforms have successfully helped over 15,000 patients worldwide in more than 60 countries, with an ongoing commitment to enhancing patient outcomes in neurovascular and peripheral interventions.

To learn more, visit Vesalio’s website.